Gümüş Güler, BaşakÖzler, Sibel2020-08-302020-08-302019Gumus Guler, B., & Ozler, S. (2019). Increased levels of serum serglycin and agrin is associated with adverse perinatal outcome in early onset preeclampsia. Fetal and pediatric pathology, 38(5), 418-431.1551-38151551-3823https://doi.org/10.1080/15513815.2019.1604922https://hdl.handle.net/20.500.12713/633Goal: Our aim was to determine whether alterations in serum serglycin and agrin levels in early-onset preeclampsia (EOPE) are useful in predicting adverse perinatal outcomes such as fetal growth restriction (FGR), intrauterine fetal demise (IUFD), preterm delivery and/or neonatal unit admission. Materials and Methods: A prospective case-controlled study enrolled 88 pregnant patients (44 EOPE and 44 controls). Maternal serum serglycin and agrin levels were determined before the 34th gestational week by enzyme-linked immunosorbent assay. Results: Compared with controls, women with EOPE had significantly higher serglycin and agrin levels (p = .018; p = .048). Multivariable logistic regression analysis revealed serglycin was independently associated with FGR in EOPE (OR 0.866; 95% CI 0.779-0.953). Agrin was independently associated with IUFD in EOPE (OR 0.757, 95% CI 0.636-0.879). Conclusions: The current study suggests that increased maternal serum serglycin is associated with FGR, and increased maternal serum agrin is associated with IUFD in EOPE.eninfo:eu-repo/semantics/closedAccessEarly Onset PreeclampsiaSerglycinAgrinFetal Growth RestrictionIntrauterine Fetal DemiseAdverse PerinatalMaternal OutcomesArticle38541843131018746WOS:0004704447000012-s2.0-85064811109Q410.1080/15513815.2019.1604922Q3